Treating risk, risking treatment: experiences of iatrogenesis in the HIV/AIDS and opioid epidemics

Anthropol Med. 2021 Jun;28(2):239-254. doi: 10.1080/13648470.2021.1926916. Epub 2021 Jun 30.

Abstract

This paper explores how poor health outcomes in the HIV/AIDS and opioid epidemics in the United States are undergirded by iatrogenesis. Data are drawn from two projects in Southern California: one among men who have sex with men (MSM) engaging with pre-exposure prophylaxis to HIV (PrEP) and the other in a public hospital system encountering patients with chronic pain and opioid use disorder (OUD). Ethnographic evidence demonstrates how efforts to minimize risk via PrEP and opioid prescription regulation paradoxically generate new forms of risk. Biomedical risk management paradigms engaged across the paper's two ethnographic field sites hinge on the production and governance of deserving patienthood, which is defined by providers and experienced by patients through moral judgments about risk underlying both increased surveillance and abandonment. This paper argues that the logic of deservingness disconnects clinical evaluations of risk from patients' lived, intersectional experiences of race, class, gender, and sexuality. This paper's analysis thus re-locates patients in the context of broader historical and sociopolitical trajectories to highlight how notions of clinical risk designed to protect patients can in fact imperil them. Misalignment between official, clinical constructions of risk and the embodied experience of risk borne by patients produces iatrogenesis.

Keywords: HIV/AIDS; Risk; iatrogenesis; opioids.

MeSH terms

  • Anthropology, Medical
  • Anti-HIV Agents / therapeutic use
  • Attitude of Health Personnel / ethnology*
  • Female
  • HIV Infections* / drug therapy
  • HIV Infections* / ethnology
  • Homosexuality, Male
  • Humans
  • Iatrogenic Disease / ethnology*
  • Male
  • Middle Aged
  • Opioid Epidemic*
  • Opioid-Related Disorders* / ethnology
  • Opioid-Related Disorders* / therapy
  • Pre-Exposure Prophylaxis
  • Risk Management
  • United States

Substances

  • Anti-HIV Agents